ch.oddb.org
 
Analysen | Apotheken | Arzt | Interaktionen | Medikamente | MiGeL | Services | Spital | Zulassungsi.
Fachinformation zu Lercanidipin-Mepha Lactab®:Mepha Pharma AG
Vollst. FachinformationDDDÄnderungen anzeigenDrucken 
Zusammens.Galen.FormInd./Anw.mögl.Dos./Anw.Kontraind.Warn.hinw.Interakt.Schwangerschaft
Fahrtücht.Unerw.WirkungenÜberdos.Eigensch.Pharm.kinetikPräklin.Sonstige H.Swissmedic-Nr.
PackungenReg.InhaberStand d. Info. 
C08CA13 - LercanidipineATC-DDD Version 2016. Source: WHO
C - Cardiovascular System
 
C08 - Calcium Channel Blockers

The calcium channel blockers are classified according to selectivity of calcium channel activity and direct cardiac effects. The ATC 4th levels are subdivided according to chemical structure.
Combinations with ergot alkaloids (C04AE) are classified in this group by using the 50-series.
Combinations with diuretics are classified in C08G.
Combinations with ACE inhibitors are classified in C09BB.
Combinations with beta blocking agents are classified in C07FB.
Combinations with statins are classified in C10BX.

The DDDs for calcium channel blockers are based on the treatment of mild-moderate hypertension, although some are used for other indications (e.g. angina pectoris).
The DDDs for oral and parenteral preparations are equal and are based on the oral dose, since oral preparations represent the major fraction of the total consumption.

C08C - Selective Calcium Channel Blockers with Mainly Vascular Effects
 
C08CA - Dihydropyridine Derivatives

Preparations containing nifedipine in combination with ergot alkaloids are classified in C08CA55.
Combinations with diuretics are classified in C08G.
Amlodipine in combination with atorvastatin is classified in C10BX03.

C08CA13 - Lercanidipine
StärkeAdm.RouteNote
10 mgO 
2018 ©ywesee GmbH
Einstellungen | Hilfe | FAQ | Anmeldung | Kontakt | Home